Zobrazeno 1 - 10
of 66
pro vyhledávání: ''
Autor:
Shannon L. Golden, Angela Tatiana Alistar, Christopher Y. Thomas, Rodwige J. Desnoyers, Alexandra Thomas, Scott Isom, Stefan C. Grant, Patricia E. Gallagher, Rhonda L. Bitting, E. Ann Tallant, Katherine Pleasant, Heidi D. Klepin, Mark C. Chappell, W. Jeffrey Petty, Janet A. Tooze
Publikováno v:
Am J Clin Oncol
Objective Preclinical studies with muscadine grape extract (MGE) show antitumor activity and decreased systemic inflammation. This phase I study (NCT02583269) assessed safety and tolerability of a proprietary MGE preparation in patients with advanced
Publikováno v:
Melanoma Research. 31:242-248
Twenty to sixty percent of patients receiving immune checkpoint inhibitors (ICIs) experience high-grade immune-related adverse events (irAEs) which may prevent the continuation of treatment. Limited clinical evidence is available to guide treatment f
Autor:
Haji Chalchal, Nicholas Chandna, Michael A. J. Moser, John Shaw, Shahid Ahmed, Kamal Haider, Adnan Zaidi, Gopinath Narasimhan
Publikováno v:
American Journal of Clinical Oncology. 44:93-98
Limited evidence is available regarding the survival benefit of second-line therapy in real world patients with advanced biliary tract and gallbladder cancer. Until very recently, there was a lack of randomized clinical trials to address this importa
Autor:
Kyung Hee Choi, Young Ah Cho, Dong Chul Kim, Ji Min Han, Young Ju Youn, Hye Sun Gwak, Sun Young Kang
Publikováno v:
Journal of Immunotherapy. 44:16-21
Although hepatotoxicity induced by immune checkpoint inhibitors (ICPIs) can cause severe clinical complications, the risk factors associated with hepatotoxicity have rarely been investigated. The purpose of this study was to determine the potential r
Autor:
William Small, Samar El Achy, Gehan A Khedr, Gayle E. Woloschak, I. Helenowksi, Jian Jun Wei, Germaine Gaber, Vamsi Parimi, Tamer Refaat, Eric D. Donnelly, Jonathan B. Strauss
Publikováno v:
American Journal of Clinical Oncology. 44:58-67
PURPOSE/OBJECTIVE The objective of this study was to assess the association between pretreatment p53, hypoxia inducible factor 1a (HIF1a), Ki-67, carbonic anhydrase-9 (CA-9), and glucose transporter 1 (GLUT1) expression in locally advanced cervical c
Autor:
Bożena Cybulska-Stopa, Piotr Rutkowski, Jacek Calik, Natasza Kempa-Kamińska, Anna M. Czarnecka, Barbara Ziółkowska, Marcin Ziętek, Jacek Mackiewicz, Łukasz Galus, Tomasz Zemełka, Tomasz Kubiatowski, Stanisław Kieszko, Karolina Piejko, Grażyna Kamińska-Winciorek, Rafał Suwiński
Publikováno v:
Melanoma Research. 31:49-57
Immunotherapy with anti-programmed cell death-1 (PD-1) agents is an effective treatment for metastatic melanoma. Octogenarians and nonagenarians represent a significant cohort of melanoma patients. This multicenter retrospective analysis enrolled 499
Autor:
Andrés Sánchez Pernaute, Luis Ortega Medina, Cristina Díaz del Arco, Lourdes Estrada Muñoz, Ricardo García Martínez, Soledad García Gómez de Las Heras, María Jesús Fernández Aceñero
Publikováno v:
American Journal of Clinical Oncology. 44:1-9
INTRODUCTION: Gastric cancer (GC) is an aggressive disease with high mortality rates. Lymph node (LN) staging of GC is a major source of controversy. The aim of this study is to compare the prognostic value of 3 different LN classifications for patie
Publikováno v:
Anti-Cancer Drugs. 31:959-965
After the failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy, some non-small cell lung cancer patients desire to receive switching with another EGFR-TKI (TKI-switching), although cytotoxic chemotherapy
Publikováno v:
American Journal of Clinical Oncology. 43:709-713
OBJECTIVE Definitive radiotherapy (RT) with or without surgery is the standard of care for solitary plasmacytoma. Here, we report clinical outcomes for this rare malignant neoplasm. PATIENTS AND METHODS We retrospectively reviewed the medical records
Autor:
Hyo Soung Cha, Jinkook Kim, Jaihwan Kim, Jin-Hyeok Hwang, Jin Won Kim, Sang Myung Woo, Dong Woo Shin, Se Yeol Yang, Jong-Chan Lee, Min Jae Kim, Ji Won Kim, Woojin Lee, Philiip Park
Publikováno v:
American Journal of Clinical Oncology. 43:654-659
Objective By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC). Methods We constructed a web-based